# Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)

**BD Alexander**[3], OA Cornely[1], PG Pappas[2], R Miller[3] , M Johnson[3], J Vazquez[4], L Ostrosky-Zeichner[5], A Spec[6], R Rautemaa-Richardson[7], R Krause[8], GR Thompson[9], TJ Walsh[10], CG Morse[11], JW Sanders[11], D Andes[12], GM Lyon[13], FM Marty[14], MH Miceli[15], TF Patterson[16], M Hoenigl[8,17], N Azie[18], DA Angulo[18]

[1]University of Cologne, [2]University of Alabama Birmingham, [3]Duke University, [4]Augusta University, [5]University of Texas Houston, [6]Washington University St. Louis, [7]University of Manchester, [8]Medical University of Graz, [9]UC Davis, [10]Cornell University, [11]Wake Forest University, [12]University of Wisconsin, [13]Emory University, [14]Brigham and Women's Hospital, [15]University of Michigan, [16]UT Health and STVHCS San Antonio, [17]University of California at San Diego, [18]SCYNEXIS, Inc.

## BACKGROUND

Ibrexafungerp is a novel class triterpenoid antifungal with activity against *Candida, Aspergillus, and Pneumocystis* species, including azole- and echinocandin-resistant strains. A Phase 3 open-label, single-arm study of oral ibrexafungerp (FURI) (Clinicaltrials.gov NCT03059992) is ongoing for the treatment of patients (≥18 years) with fungal diseases who are intolerant of or refractory to standard antifungal therapies.

## METHODS

### Study Design




An independent Data Review Committee (DRC) provided an assessment of treatment response for 41 patients who completed therapy by October 2019. Patients were enrolled in 22 centers from six countries. Patients were eligible for enrollment if they had proven or probable, invasive or severe mucocutaneous candidiasis and documented evidence of failure of, intolerance to, or toxicity related to a currently approved standard-of-care antifungal treatment or could not receive approved oral antifungal options (e.g., susceptibility of the organism) and a continued IV antifungal therapy was undesirable or unfeasible due to clinical or logistical circumstances.

## RESULTS

### Demographics

Per Table 1, of the 41 patients analyzed, 22 (54%) were enrolled with invasive candidiasis/candidemia and 19 (46%) with mucocutaneous candidiasis infections; 70% of patients were immunocompromised.

**Table 1: FURI Study Patient Demographics**

| Demographics | Ibrexafungerp |
|---|---|
| Patients (No.) | 41 |
| Mean Days of Therapy | 37.2 |
| **Site of Infection** | **# of Patients** |
| Intraabdominal candidiasis | 7 |
| Intraabdominal + candidemia | 1 |
| Candidemia* | 6 |
| Hepato-splenic | 2 |
| Osteoarticular | 3 |
| Endocarditis, Mediastinitis, Cystitis | 1 (each) |
| Oropharyngeal | 8 |
| Esophageal | 7 |
| Chronic mucocutaneous | 2 |
| Wound infection | 2 |

*One patient with candidemia had UTI

### Outcomes

Of the 41 patients analyzed, oral ibrexafungerp showed clinical benefit in 34 patients (83%), including patients with a complete or partial response and patients who maintained stable disease. Six patients (15%) did not respond to the ibrexafungerp treatment (one patient was considered indeterminate).

**Table 2: FURI Study Outcomes**

| | Complete/ Partial Response | Stable Disease | Progression of Disease | Indeterminate |
|---|---|---|---|---|
| All Patients (41) | 23 (56%) | 11 (27%) | 6 (15%) | 1 (2%) |

*Candida glabrata* was the most common pathogen isolated, representing 54% of the 46 *Candida* species recovered from these patients. 32 patients were infected with one species while two species were isolated in 7 (18%) patients.

**Table 3: FURI Study Outcomes by Pathogen**

| Pathogen (n) | Complete/Partial Response | Stable Disease | Progression of Disease |
|---|---|---|---|
| ***C. glabrata* (17)** | 9 | 5 | 3 |
| ***C. albicans* (7)** | 5 | 2 | |
| ***C. krusei* (5)** | 2 | 3 | |
| ***C. parapsilosis* (3)** | 3 | | |
| **Two Pathogens** | | | |
| ***C. glabrata/C. albicans* (4)** | 2 | | 2 |
| ***C. krusei/C. albicans* (1)** | 1 | | |
| ***C. tropicalis/C. albicans* (1)** | | 1 | |
| ***C. glabrata/C. dubliniensis* (1)** | | | 1 |

1 patient outcome indeterminate, 1 patient's organism not identified

### Safety

Ibrexafungerp was well-tolerated with the most common treatment-related adverse events being of gastrointestinal origin. No deaths due to progressive fungal disease were reported.

## CONCLUSIONS

Preliminary analysis of these 41 cases indicate that oral ibrexafungerp provides a favorable therapeutic response in the majority of patients with difficult to treat *Candida* spp. infections, including those caused by non-*albicans Candida* species.

*For additional information contact SCYNEXIS at info@scynexis.com*